Targeting Mtor With Curcumin: Therapeutic Implications for Complex Diseases Publisher Pubmed



Khayatan D^{1, 2} ; Razavi SM^{1, 2} ; Arab ZN^{1, 2} ; Nasoori H^{1, 2} ; Fouladi A^{2, 3} ; Pasha AVK^{1, 2} ; Butler AE⁴ ; Karav S⁵ ; Momtaz S^{2, 6, 7} ; Abdolghaffari AH^{1, 2} ; Sahebkar A^{8, 9, 10}
Source: Inflammopharmacology Published:2025

Abstract

The mammalian target of rapamycin (mTOR) is a crucial enzyme in regulating multiple signaling pathways in the body, including autophagy, proliferation and apoptosis. Disruption of these mTOR signaling pathways can lead to an array of abnormalities and trigger disease processes, examples being neurodegenerative conditions, cancer, obesity and diabetes. Under conditions of oxidative stress, mTOR can regulate apoptosis and autophagy, with tissue repair being favored under such circumstances. Moreover, the correlation between mTOR and other signaling pathways could play a pivotal role in the pathophysiology of numerous disorders. mTOR has a tight connection with NF-κB, Akt, PI3K, MAPK, GSK-3β, Nrf2/HO-1, JAK/STAT, CREB/BDNF, and ERK1/2 pathways, which together could play significant roles in the regulation of inflammation, apoptosis, cell survival, and oxidative stress in different body organs. Research suggests that inhibiting mTOR could be beneficial in treating metabolic, neurological and cardiovascular conditions, as well as potentially extending life expectancy. Therefore, identifying new chemicals and agents that can modulate the mTOR signaling pathway holds promise for treating and preventing these disorders. Curcumin is one such agent that has demonstrated regulatory effects on the mTOR pathway, making it an exciting alternative for reducing complications associated with complex diseases by targeting mTOR. This review aims to examine the potential of curcumin in modulating the mTOR signaling pathway and its therapeutic implications. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025.